Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis

Alimentary Pharmacology and Therapeutics

Volumn 47, Issue 5, 2018, Pages 645-656

  Hameed, B ^a   Terrault, N A ^a,f   Gill, R M ^a   Loomba, R ^b   Chalasani, Naga ^f   Hoofnagle, J H ^d   Van Natta, M L ^e   Allende, Daniela ^f   Dasarathy, Srinivasan ^f   J McCullough, Arthur ^f   Penumatsa, Revathi ^f   Dasarathy, Jaividhya ^f   E Lavine, Joel ^f   F Abdelmalek, Manal ^f   Bashir, Mustafa ^f   Buie, Stephanie ^f   Mae Diehl, Anna ^f   Guy, Cynthia ^f   Kigongo, Christopher ^f   Kopping, Mariko ^f   Malik, David ^f   Piercy, Dawn ^f   W Cummings, Oscar ^f   Gawrieh, Samer ^f   Ragozzino, Linda ^f   Sandrasegaran, Kumar ^f   Vuppalanchi, Raj ^f   M Brunt, Elizabeth ^f   Cattoor, Theresa ^f   Carpenter, Danielle ^f   Freebersyser, Janet ^f   King, Debra ^f   Lai, Jinping ^f   A Neuschwander Tetri, Brent ^f   Siegner, Joan ^f   Stewart, Susan ^f   Torretta, Susan ^f   Wriston, Kristina ^f   Cardona Gonzalez, Maria ^f   Davila, Jodie ^f   Jhaveri, Manan ^f   V Kowdley, Kris ^f   Mukhtar, Nizar ^f   Ness, Erik ^f   Poitevin, Michelle ^f   Quist, Brook ^f   Soo, Sherilynn ^f   Ang, Brandon ^f   Behling, Cynthia ^f   Bhatt, Archana ^f   Loomba, Rohit ^f   S Middleton, Michael ^f   Sirlin, Claude ^f   F Akhter, Maheen ^f   M Bass, Nathan ^f   Brandman, Danielle ^f   Gill, Ryan ^f   Hameed, Bilal ^f   Maher, Jacqueline ^f   Ungermann, Ashley ^f   Yeh, Matthew ^f   Boyett, Sherry ^f   J Contos, Melissa ^f   Kirwin, Sherri ^f   Ac Luketic, Velimir ^f   Puri, Puneet ^f   J Sanyal, Arun ^f   Schlosser, Jolene ^f   S Siddiqui, Mohammad ^f   Yost Schomer, Leslie ^f   Fowler, Kathryn ^f   E Kleiner, David ^f   C Doo, Edward ^f   Hall, Sherry ^f   H Hoofnagle, Jay ^f   Lee, Jessica J ^f   R Robuck, Patricia ^f   H Sherker, Averell ^f   Torrance, Rebecca ^f   Belt, Patricia ^f   M Clark, Jeanne ^f   Dodge, John ^f   Donithan, Michele ^f   Hallinan, Erin ^f   Isaacson, Milana ^f   Lazo, Mariana ^f   Meinert, Jill ^f   Miriel, Laura ^f   Smith, Jacqueline ^f   Smith, Michael ^f   Sternberg, Alice ^f   Tonascia, James ^f   L Van Natta, Mark ^f   Wagoner, Annette ^f   A Wilson, Laura ^f   Yamada, Goro ^f   Yates, Katherine ^f   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INDIANA UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OBETICHOLIC ACID; PLACEBO; CHENODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT LOSS; CONTROLLED STUDY; DIARRHEA; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; POST HOC ANALYSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VOMITING; ANALOGS AND DERIVATIVES; BIOPSY; BLOOD; BODY WEIGHT; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ALKALINE PHOSPHATASE; BIOPSY; BODY WEIGHT; CHENODEOXYCHOLIC ACID; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 85040659151     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14492     Document Type: Article

References (22)

1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
2. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr. 2013;162:496-500.e1.
3. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643-654. e641-649; quiz e639-640.
4. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547-555.
5. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357-1365.
6. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. American Association for the Study of Liver D, United States F, Drug. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392-1405.
7. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147-191.
8. Mencarelli A, Renga B, D'Amore C, et al. Dissociation of intestinal and hepatic activities of FXR and LXRalpha supports metabolic effects of terminal ileum interposition in rodents. Diabetes. 2013;62:3384-3393.
9. Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039-11049.
10. Pellicciari R, Costantino G, Camaioni E, et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem. 2004;47:4559-4569.
11. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51:771-784.
12. Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59:2286-2298.
13. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574-582.
14. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956-965.
15. Hoofnagle JH, van Natta ML, Kleiner DE, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38:124-143.
16. Kleiner DE, Brunt EM, van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
17. Cleophas TJ, Zwinderman AH, van Ouwerkerg B, Sobh M. Cardiovascular drug trials: how to examine interaction, and why so. Neth Heart J. 2007;15:61-66.
18. Bender R, Lange S. Adjusting for multiple testing: when and how? J Clin Epidemiol. 2001;54:343-349.
19. Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631-643.
20. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res. 2012;53:1723-1737.
21. Hageman J, Herrema H, Groen AK, Kuipers F. A role of the bile salt receptor FXR in atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:1519-1528.
22. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;28:503-522.